Latest Articles
Twenty-Year-Old Orphan Has a Pre-Op Appointment in Three Days for Disabling Endometriosis — Her Grandmother Who Raised Her Just Threatened to Withhold the Ride After She Stuck Up for Her Brother - AOL.com
Twenty-Year-Old Orphan Has a Pre-Op Appointment in Three Days for Disabling Endometriosis — Her Grandmother Who Raised Her Just Threatened to Withhold the Ride After She Stuck Up for Her …
Published: May 14, 2026, 7:10 p.m.
Barbara Palvin and Dylan Sprouse share baby news at Cannes - Geo News
Barbara Palvin and Dylan Sprouse share baby news at Cannes Geo News
Published: May 14, 2026, 7:08 p.m.
Barbara Palvin and Dylan Sprouse announce pregnancy at Cannes Film Festival - The Express Tribune
Barbara Palvin and Dylan Sprouse announce pregnancy at Cannes Film Festival The Express Tribune
Published: May 14, 2026, 6:48 p.m.
PHOTOS: Dylan Sprouse's Wife Barbara Palvin Announces 1st Pregnancy & Debuts Baby Bump on Cannes Red Carpet - EntertainmentNow
PHOTOS: Dylan Sprouse's Wife Barbara Palvin Announces 1st Pregnancy & Debuts Baby Bump on Cannes Red Carpet EntertainmentNow
Published: May 14, 2026, 6:47 p.m.
Barbara Palvin Is Pregnant, Expecting First Baby With Dylan Sprouse - E! Online
Barbara Palvin Is Pregnant, Expecting First Baby With Dylan Sprouse E! Online
Published: May 14, 2026, 5:58 p.m.
Dylan Sprouse and Wife Barbara Palvin Expecting Their First Baby Together - People.com
Dylan Sprouse and Wife Barbara Palvin Expecting Their First Baby Together People.com
Published: May 14, 2026, 5:54 p.m.
In-Office Nitrous Oxide Linked to Fewer OR Ob/Gyn Procedures - Medscape
In-Office Nitrous Oxide Linked to Fewer OR Ob/Gyn Procedures Medscape
Published: May 14, 2026, 1:22 p.m.
Maipl Therapeutics Reports Preclinical Progress for MA-4604, a Novel Oral Non-Hormonal Treatment of Endometriosis - Newswise
Maipl Therapeutics Reports Preclinical Progress for MA-4604, a Novel Oral Non-Hormonal Treatment of Endometriosis Newswise
Published: May 14, 2026, 12:40 p.m.
Karyopharm Therapeut Reports Q1 2026: $35.1M Revenue, $29.2M U.S. Product Sales, Net Loss $22.4M - TradingView
Karyopharm Therapeut Reports Q1 2026: $35.1M Revenue, $29.2M U.S. Product Sales, Net Loss $22.4M TradingView
Published: May 14, 2026, 11:33 a.m.
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment - PR Newswire
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment PR Newswire
Published: May 14, 2026, 11:30 a.m.
Link copied to clipboard!